Journals / 3 P/ Psikiyatri Psikoloji Psikofarmakoloji Dergisi / 2003 / Cilt: 11 - Sayı: supp3

Quetiapine in bipolar disorders

Bipolar bozuklukta ketiapin kullanımı

Pages
39–44
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this article, based on the information available in the literature, treatment of bipolar disorder and particularly the role of atypical agent quetiapine in treatment of this disorder were reviewed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Despite the advances in treatment of bipolar disorder, available treatment options are not always effective or associated with side effects leading to incompliance with the treatment.
📊
Key Findings & Data:As well as mood stabilizers such as lithium, valproate and carbamazepine, neuroleptics are widely used in acute and maintenance treatment of bipolar disorder.
💡
Conclusion & Impact:In this article, based on the information available in the literature, treatment of bipolar disorder and particularly the role of atypical agent quetiapine in treatment of this disorder were reviewed.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Despite the advances in treatment of bipolar disorder, available treatment options are not always effective or associated with side effects leading to incompliance with the treatment. As well as mood stabilizers such as lithium, valproate and carbamazepine, neuroleptics are widely used in acute and maintenance treatment of bipolar disorder. Side effects due to antipsychotics further complicate the treatment of the disorder. Considering these problems with the use of classical antipsychotic agents in that they carry a lower risk of side effects. In this article, based on the information available in the literature, treatment of bipolar disorder and particularly the role of atypical agent quetiapine in treatment of this disorder were reviewed.

Özet

Bipolar bozukluğun tedavisindeki ilerlemelere rağmen, varolan tedaviler her zaman etkin değildir ya da tedaviye uyumsuzluğa yol açan yan etkilerle birliktedir. Lityum, valproat ve karbamazepin gibi duygudurum düzenleyicilerin yanı sıra nöroleptikler de bipolar bozukluğun akut ve idame tedavisinde yaygın olarak kullanılmışlardır. Ne var ki, klasik antipsikotiklerle ortaya çıkan yan etkiler bipolar bozukluk tedavisini daha da karmaşık bir hale getirmiştir. Klasik antipsikotik ajanların kullanımına ilişkin bu sorunlar güz önüne alındığında, atipik antipsikotik ajanlar düşük yan etki riski taşımalarından ötürü tipik antipsikotik ajanların çekici bir alternatifi haline gelebilirler. Bu makalede, bipolar bozukluk tedavisi ve özellikle atipik antipsikotik ajan ketiapinin tedavideki yeri literatür ışığında gözden geçirilmiştir.

🔖

Cite This Article

AKDEMİR, A., GÜRİZ, O., KARAOĞLAN, A. (2022). Quetiapine in bipolar disorders. 3 P/ Psikiyatri Psikoloji Psikofarmakoloji Dergisi, Cilt: 11 - Sayı: supp3, 39–44. https://ajindex.com/articles/426283

References (17)

  1. Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KN, Daniel DG ve ark. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 1999
  2. Kusumakar V,Yatham L, Haslam D, Parikh S, Matte R, Sharma V ve ark. The Foundations of effective management of bipolar disorder. Can J Psychiatry 1997
  3. 42 (Suppl 2):69S-73S. 3.Sanger TM, Grundy SL, Gibson PJ, Namjoshi MA, Greaney MG, Tohen MF. Long-term olanzapine therapy in the treatment of bipolar I disorder: An open-label continuation phase study. J Clin Psychiatry 2001
  4. Keller MB. The course of manic-depressive illness. J Clin Psychiatry 1988
  5. 49 (Suppl ll):4-6. 5.Gitlin MJ, Swendsen J, Heller Tl, Hammen C. Relapse and impairment in bipolar disorder. Am J Psychiatry 1995
  6. Parikh SV, Kusumakar V, Haslam D, Matte R, Sharma V, Yatham LN. Psychosocial interventions as an adjunct to phar-macotherapy in bipolar disorder. Can J Psychiatry 1997:42 (Suppl 2):74S-78S. 7.Pharma V, Yatham LN, Haslam D, Silverstone PH, Parikh S, Matte R ve ark. Continuation and prophylactic treatment of bipolar disorder. Can J Psychiatry 1997
  7. 42 (Suppl 2):92S-100S. 8.Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG ve ark. Efficacy of olanzapine in acute bipolar mania. Arch Gen Psychiatry 2000
  8. White E, Cheung P, Silverstone T. Depot antipsychotics in bipolar affective disorder. Int Clin Psychopharmacol 1993
  9. Soares JC, Mallinger AG, Gershon S. The role of antipsychotic agents in the treatment of bipolar disorder patients. Int Clin Psychopharmacol 1997
  10. Pope HG, McElroy SL, Keck PE, Hudson JI. Valproate in the treatment of acute mania. Arch Gen Psychiatry 1991
  11. Ayşegül Özerdem. Manik epizod sağaltımı. Psikiyatri Psikoloji Psikofarmakoloji Dergisi 2000
  12. 8 (Ek 3):8-12. 13.Zarate CA, Narendran R, Tohen M, Greaney JJ, Berman A, Pike S ve ark. Clinical Predictors of acute response with olanzapine in psychotic mood disorders. J Clin Psychiatry 1998
  13. 1 (24-28). 14.Tohen M, Zarate CA. Antipsychotic agents and bipolar disorder. J Clin Psychiatry 1998
  14. 59 (suppl 1):38-48. 15.Post RM. Non-lithium treatment for bipolar disorder. J Clin Psychiatry 1990
  15. 51 (8 Suppl):9-16. 16.Tohen M, Grundy S. Management of acute mania. J Clin Psychiatry!999
  16. 60 (Suppl 5): 31-34. 17.Niedermier JA, Nasrallah HA. Clinical correlates of response to valproate in geriatric Patients. Ann Clin Psychiatry 1998
  17. Calabrese J.R, Shelton M